Webinar: Quantitative live-cell imaging using automated liquid dispensing
Overview
To create a large biobank, reliable culture and analysis methods are required, including robust quality control assays to evaluate the key characteristics of the organoid disease model created. Historically, the characterization and optimization of such assays have been limited in throughput and subject to qualitative assessment.
To overcome this barrier, a reproducible quantitative high-throughput solution is required. In this webinar we demonstrate using cancer and intestinal organoid models and how the Incucyte® SX5 live-cell microscopy system (Sartorius) was implemented to monitor and automatically quantify the organoid growth kinetics and changes in morphology upon differentiation for their quality control assessment.
Join us to:
- Learn more about biobanks and bespoke downstream application assays for organoid disease models
- Explore a reproducible high-throughput solution for robust quality control assays
- Discover how to monitor and automatically quantify organoid growth kinetics and changes in morphology
Key Takeaways
This webinar will benefit:
- Anyone interested in the importance of organoids in disease modelling
- Anyone working with complex 3D advanced cell models
- Everyone who needs deeper insights into their live cell assays
Webinar Speaker
Dr. Maryna Panamarova
Technical Specialist, Cellular Generation
Wellcome Sanger Institute
Maryna holds a BSc in Molecular Biology and a PhD in Human Embryonic Stem Cell Epigenetics and has worked in mouse and human embryonic stem cell and induced pluripotent stem cell biology for 15 years. Maryna joined the Wellcome Trust Sanger Institute in 2020, initially leading the science development of a high throughput method producing iPSC-derived neuronal models, then moved to upscaling and automating the derivation and culture of patient- and iPSC-derived organoid models. Maryna is working across multiple high-scale organoid production projects to generate organoid biobanks, addressing the unmet clinical needs in inflammatory bowel disease, endometriosis and skin diseases.
